The Potential Economic Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling

INTRODUCTION: Alzheimer’s disease (AD) is a progressive, neurodegenerative disease that affects memory, thinking, and behavior and places a substantial economic burden on caregivers and healthcare systems. This early-phase study aimed to model lecanemab, a humanized monoclonal antibody targeting amy...

Descripción completa

Detalles Bibliográficos
Autores principales: Tahami Monfared, Amir Abbas, Tafazzoli, Ali, Chavan, Ameya, Ye, Weicheng, Zhang, Quanwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338185/
https://www.ncbi.nlm.nih.gov/pubmed/35718854
http://dx.doi.org/10.1007/s40120-022-00373-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338185/
https://www.ncbi.nlm.nih.gov/pubmed/35718854
http://dx.doi.org/10.1007/s40120-022-00373-5

Ejemplares similares